An interventional study of Pituitrin infusion and Norepinephrine infusion in Postoperative Vasoplegic Syndrome, sponsored by Beijing Anzhen Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-10-11.
Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment
Vasoplegic syndrome is a common complication after cardiac surgery. Low dose vasopressin can up-regulate blood pressure and improve clinical outcomes compared with norepinephrine (mainly acute kidney injury Anesthesiology 2017; 126:85-93). Pituitrin is used as a substitute for vasopressin in our center, which contains both vasopressin and oxytocin. Oxytocin may alleviate inflammatory process-associated kidney injury (Peptides 2006;27:2249-57). Therefore, the investigators hypothesize Pituitrin may be preferable to norepinephrine in the renal protection of patients with vasoplegic syndrome after cardiac surgery. Moreover, the serum levels of vasopressin, catecholamine, corticosteroid and corticotropin-releasing hormone will be measured.
48 studies on the registry are indexed under Vasoplegia; 19 are open to participants now.
This study's planned enrollment of 120 is close to the median of 110 across 27 interventional studies indexed under Vasoplegia.
Browse Vasoplegia studies →Beijing Anzhen Hospital is the lead sponsor of 192 studies on the registry; 102 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
Drug: Pituitrin infusion
To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
Drug: Norepinephrine infusion
To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
Rate of in-hospital acute renal injury
Acute renal injury (AKI) is defined as any of the following: (1) increase in serum creatinine (SCr) by ≥ 26.5lmol/l in 48 hours; (2) increase in SCr to ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or (3) urine output \< 0.5 ml/kg/h for 6 hours (urine output is only assessed when the CRRT machine is absent or with a fluid removal rate of 0 ml/h).
Time frame: 30 days
In-hospital mortality
All-cause mortality
Time frame: 30 days
Rate of new arrhythmias
Rate of new arrhythmias after cardiac surgery
Time frame: 30 days
Hormone levels
Serum hormone levels after cardiac surgery, including vasopressin, catecholamine, corticosteroid and corticotropin-releasing hormone
Time frame: 30 days
Rate of ECMO or LVAD support
Receiving extracorporeal membrane oxygenation (ECMO) or left ventricle assist device (LVAD) support
Time frame: 30 days
Duration on ventilator support
Duration on ventilator support after cardiac surgery
Time frame: 30 days
ICU length of stay
ICU length of stay
Time frame: 30 days
Hospital length of stay after cardiac surgery
Hospital length of stay after cardiac surgery
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2017 (actual). Primary completion is estimated for Dec 2018, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Norepinephrine